Literature DB >> 18454349

Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Ivo Santana Caldas1, André Talvani, Sérgio Caldas, Cláudia Martins Carneiro, Marta de Lana, Paulo Marcos da Matta Guedes, Maria Terezinha Bahia.   

Abstract

The goals of this study were to evaluate the efficacy of benznidazole (Bz) treatment in decreasing of the parasitic load during the acute phase of experimental Chagas disease and to analyze its influence in the development of cardiac chronic alterations in mice inoculated with drug-resistant Trypanosoma cruzi strains. Our results showed that the early Bz treatment (started at 4th day of infection) was efficient in reducing the parasite load in animals from both acute and chronic phase of the infection. Moreover, this reduction in the parasite load could not be associated with the intensity of the cardiac chronic lesions. The histopathological evaluation of cardiac tissue of Bz-treated mice showed three different patterns of response: (1) presence of a small number of inflammatory cells and fibrotic area similar to noninfected mice; (2) similar intensity of inflammatory infiltrate and smaller fibrotic area in relation to nontreated animals; (3) similar intensity of inflammatory infiltrated and fibrosis area among the Bz-treated and nontreated animals. Each specific pattern was obtained with different T. cruzi strain, suggesting that the pattern of the heart lesions in chronic phase of Bz-treated animals was T. cruzi strain dependent but not related with drug resistance levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454349     DOI: 10.1007/s00436-008-0992-6

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  36 in total

1.  Trypanosoma cruzi: sensitivity of the polymerase chain reaction for detecting the parasite in the blood of mice infected with different clonal genotypes.

Authors:  C T Miyamoto; M L Gomes; A V Marangon; S M Araújo; M T Bahia; M Lana; M J O Toledo
Journal:  Exp Parasitol       Date:  2005-12-22       Impact factor: 2.011

Review 2.  Pathogenesis of Chagas heart disease: role of autoimmunity.

Authors:  David M Engman; Juan S Leon
Journal:  Acta Trop       Date:  2002-02       Impact factor: 3.112

3.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  [Experimental study on the resistance of a strain of Trypanosoma cruzi to Bay 2502].

Authors:  S G Andrade; Z A Andrade; R M Figueira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1977 Mar-Apr       Impact factor: 1.846

5.  [Acute Chagas' disease: transmission routes, clinical aspects and response to specific therapy in diagnosed cases in an urban center].

Authors:  M A Shikanai-Yasuda; M H Lopes; J E Tolezano; E Umezawa; V Amato Neto; A C Barreto; Y Higaki; A A Moreira; G Funayama; A A Barone
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1990 Jan-Feb       Impact factor: 1.846

6.  [Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole].

Authors:  H de O Ferreira
Journal:  Rev Soc Bras Med Trop       Date:  1990 Oct-Dec       Impact factor: 1.581

7.  Vascular and cellular responses to pro-inflammatory stimuli in rat dental pulp.

Authors:  Kátia L M Maltos; Gustavo B Menezes; Marcelo V Caliari; Orivaldo A Rocha; Júlia M M Santos; Dalton L F Alves; Igor D G Duarte; Janetti N Francischi
Journal:  Arch Oral Biol       Date:  2004-06       Impact factor: 2.633

8.  Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole.

Authors:  Sérgio Caldas; Fabiane M Santos; Marta de Lana; Lívia F Diniz; George L L Machado-Coelho; Vanja M Veloso; Maria T Bahia
Journal:  Exp Parasitol       Date:  2007-09-07       Impact factor: 2.011

9.  Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains.

Authors:  S G Andrade; A Rassi; J B Magalhaes; F Ferriolli Filho; A O Luquetti
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

10.  Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment.

Authors:  M A Segura; E Molina de Raspi; M A Basombrio
Journal:  Mem Inst Oswaldo Cruz       Date:  1994 Apr-Jun       Impact factor: 2.743

View more
  28 in total

1.  Lychnopholide in Poly(d,l-Lactide)-Block-Polyethylene Glycol Nanocapsules Cures Infection with a Drug-Resistant Trypanosoma cruzi Strain at Acute and Chronic Phases.

Authors:  Renata Tupinambá Branquinho; Carlos Geraldo Campos de Mello; Maykon Tavares Oliveira; Levi Eduardo Soares Reis; Paula Mello de Abreu Vieira; Dênia Antunes Saúde-Guimarães; Vanessa Carla Furtado Mosqueira; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Combination Therapy Using Benznidazole and Aspirin during the Acute Phase of Experimental Chagas Disease Prevents Cardiovascular Dysfunction and Decreases Typical Cardiac Lesions in the Chronic Phase.

Authors:  Rito Santo Pereira; Aparecida Donizette Malvezi; Maria Isabel Lovo-Martins; Bruno Fernando Cruz Lucchetti; Jussevania Pereira Santos; Eliandro Reis Tavares; Waldiceu Aparecido Verri; Eduardo José de Almeida Araújo; Lucy Megumi Yamauchi; Sueli Fumie Yamada-Ogatta; Marli Cardoso Martins-Pinge; Phileno Pinge-Filho
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Effects of Trypanosoma cruzi infection on myocardial morphology, single cardiomyocyte contractile function and exercise tolerance in rats.

Authors:  Rômulo D Novaes; Arlete R Penitente; Reggiani V Gonçalves; André Talvani; Clóvis A Neves; Izabel R S C Maldonado; Antônio J Natali
Journal:  Int J Exp Pathol       Date:  2011-07-08       Impact factor: 1.925

4.  Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.

Authors:  Maria T Bahia; Alvaro F S Nascimento; Ana Lia Mazzeti; Luiz F Marques; Karolina R Gonçalves; Ludmilla W R Mota; Lívia de F Diniz; Ivo S Caldas; André Talvani; David M Shackleford; Maria Koltun; Jessica Saunders; Karen L White; Ivan Scandale; Susan A Charman; Eric Chatelain
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

5.  Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.

Authors:  Ana Paula Gruendling; Miyoko Massago; Ana Paula M Teston; Wuelton M Monteiro; Edilson N Kaneshima; Silvana M Araújo; Mônica L Gomes; Maria das Graças V Barbosa; Max Jean O Toledo
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

6.  Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.

Authors:  Lívia de Figueiredo Diniz; Ivo Santana Caldas; Paulo Marcos da Matta Guedes; Geovam Crepalde; Marta de Lana; Cláudia Martins Carneiro; André Talvani; Julio Alberto Urbina; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

7.  Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.

Authors:  Rômulo Dias Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Jerusa M Oliveira; Thaís V Carvalho; Mariana M Neves; Leandro L Oliveira; André Talvani
Journal:  Parasitol Res       Date:  2015-04-28       Impact factor: 2.289

8.  Clinical outcomes of thirteen patients with acute chagas disease acquired through oral transmission from two urban outbreaks in northeastern Brazil.

Authors:  Claudilson J C Bastos; Roque Aras; Gildo Mota; Francisco Reis; Juarez Pereira Dias; Robson Silva de Jesus; Miralba Silva Freire; Eline G de Araújo; Juliana Prazeres; Maria Fernanda Rios Grassi
Journal:  PLoS Negl Trop Dis       Date:  2010-06-15

9.  In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.

Authors:  Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Marcos Meuser Batista; Beatriz Philot Pavão; Julianna Siciliano Araújo; Claudia Alessandra Fortes Aiub; Patrícia Bernardino da Silva; Jessica Lionel; Constança Britto; Kwangho Kim; Gary Sulikowski; Tatiana Y Hargrove; Michael R Waterman; Galina I Lepesheva
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

10.  Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.

Authors:  F H Guedes-da-Silva; D G J Batista; C F da Silva; M B Meuser; M R Simões-Silva; J S de Araújo; C G Ferreira; O C Moreira; C Britto; G I Lepesheva; Maria de Nazaré C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.